Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
19
10
2022
accepted:
28
02
2023
revised:
23
02
2023
medline:
11
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population. This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p < 0.001). T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. IPSS-R and the WHO classification differentiated t-MDS into different risk groups. As compared with controls, MDS patients had a six-fold increased prevalence of a previous hematological malignancy but only a 34% increased prevalence of a previous solid tumor. T-MDS patients with a previous hematological malignancy had a dismal prognosis, due both to mortality related to their primary disease and to high-risk MDS.
Identifiants
pubmed: 36928008
doi: 10.1038/s41375-023-01864-6
pii: 10.1038/s41375-023-01864-6
pmc: PMC10169633
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103-1112Informations de copyright
© 2023. The Author(s).
Références
Blood Adv. 2021 Oct 26;5(20):4140-4148
pubmed: 34492705
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Haematologica. 2020 Mar;105(3):e98-e101
pubmed: 31413096
J Clin Oncol. 2003 Oct 1;21(19):3601-8
pubmed: 12913100
J Clin Oncol. 2014 Aug 20;32(24):2662-8
pubmed: 25071099
Nat Rev Cancer. 2017 Aug 24;17(9):513-527
pubmed: 28835720
Leukemia. 2017 Jun;31(6):1391-1397
pubmed: 28111463
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2014 Jan;28(1):185-9
pubmed: 23787392
Hemasphere. 2021 Jun 01;5(6):e578
pubmed: 34095761
Leukemia. 2021 Mar;35(3):835-849
pubmed: 32595214
Clin Epidemiol. 2021 Jan 12;13:21-41
pubmed: 33469380
Blood Adv. 2022 Apr 26;6(8):2657-2666
pubmed: 35042239
Cancer. 2016 Jan 15;122(2):304-11
pubmed: 26641009
Nature. 2015 Feb 26;518(7540):552-555
pubmed: 25487151
Am J Clin Pathol. 2007 Feb;127(2):197-205
pubmed: 17210514
Br J Haematol. 2018 Jun;181(5):614-627
pubmed: 29707769
Blood. 2017 Dec 7;130(23):2475-2483
pubmed: 29212804
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
J Clin Oncol. 2012 Jul 1;30(19):2340-7
pubmed: 22585703
Radiother Oncol. 2009 Nov;93(2):153-67
pubmed: 19765845
Blood. 2003 Jul 1;102(1):43-52
pubmed: 12623843
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10
pubmed: 24875590
Leuk Lymphoma. 2015 Jun;56(6):1643-50
pubmed: 25308294
Eur J Haematol. 2021 Aug;107(2):275-282
pubmed: 33966293
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
JAMA Oncol. 2019 Mar 1;5(3):318-325
pubmed: 30570657
Best Pract Res Clin Haematol. 2019 Mar;32(1):98-103
pubmed: 30927980
Leuk Res. 2018 Nov;74:130-136
pubmed: 30055822
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897